# SNIFF - Combo INI+EMPA Trial

> **NCT05081219** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 47 (actual)

## Conditions studied

- Mild Cognitive Impairment
- Cognitive Impairment
- Alzheimer Disease

## Interventions

- **DRUG:** Insulin (Humulin® R U-100)
- **DRUG:** Empagliflozin 10 MG
- **DEVICE:** Aptar Pharma CPS Intranasal Delivery Device
- **DRUG:** Placebo (Insulin Diluent)
- **DRUG:** Placebo (Capsules)

## Key facts

- **NCT ID:** NCT05081219
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-14
- **Primary completion:** 2024-09-17
- **Final completion:** 2024-09-17
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05081219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05081219, "SNIFF - Combo INI+EMPA Trial". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05081219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*